USRE29077E - Tablet formulation - Google Patents
Tablet formulation Download PDFInfo
- Publication number
- USRE29077E USRE29077E US05/666,559 US66655976A USRE29077E US RE29077 E USRE29077 E US RE29077E US 66655976 A US66655976 A US 66655976A US RE29077 E USRE29077 E US RE29077E
- Authority
- US
- United States
- Prior art keywords
- tablet
- weight
- percent
- tablets
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
Definitions
- This invention relates to novel formulations for tablets which are to be deeply grooved. Deeply grooved tablets are those in which the groove is one-third to two-thirds of the total tablet thickness. Such tablets are shown for instance in U.S. Pat. No. 224,591 and in copending applications Ser. No. 386,142 filed Aug. 6, 1973 which is a continuation-in-part of Ser. No. 312,065 filed Dec. 4, 1972 and now abandoned which was in turn a combination of Ser. No. 114,926 filed Feb. 12, 1971 and Ser. No. 124,894 filed Mar. 16, 1971. The foregoing patent and applications were all filed by Edwin F. Roberts and assigned to the assignee of this application. The tablet design allows for easy, simple and accurate division of a pharmaceutical tablet.
- a groove, or bisect, or score may be formed on one of the tablet faces.
- the groove facilitates breaking of the tablet into two parts by applying pressure while the tablet is held between two fingers or in both hands.
- dividing a tablet into two or more accurate predetermined parts permits the administration of two or more doses of the active ingredient, or drug, contained in the tablet.
- Potent drugs are frequently incorporated in small amounts into a total tablet formulation, and the capability to divide the tablet accurately allows for a saving by not having to formulate, package and distribute different sized tablets for a portion of the dose and for the full dose.
- the inclusion of one-half of that dose in a tablet of similar size decreases the relation of drug to excipients twofold, thus in many cases also increasing the possibility of drug degradation due to drug-excipient interaction.
- FIG. 1 is an isometric view of a pharmaceutical tablet employing a deeply scored design
- FIG. 2 is a top plan view thereof
- FIG. 3 is a side elevational view thereof as seen at right angles to FIG. 2;
- FIG. 4 is an end elevational view thereof as seen at right angles to FIG. 2;
- FIG. 5 is an end elevational view of a pharmaceutical tablet embodying a modification of the form illustrated in FIG. 4;
- FIG. 6 is a bottom view of the embodiments of FIGS. 1 and 5.
- the deeply grooved tablet design presents tablet compression characteristics which are not typical of the manufacturing of conventional pharmaceutical tablets. While tablets are usually compacted between uniform surfaces, flat or concave, the deeply grooved tablet design presents a non-uniform compressing surface on one tablet face and a uniform face, spherical or flat, on the other.
- Such a multiplanar surface presents a process of physical compaction which does not produce the results expected from a conventional compressed tablet. In the process of compaction, the multiplanar surface applies forces, the resultant of which is not vertical. This results in non-uniform stress distribution within the tablet as an independent unit which in turn causes tablet capping and the inadequate imprinting or embossing of indicia of any of its surfaces.
- “Picking” and “sticking” are words of art, meaning part of the tablet sticks to the tips of the upper or lower punch. "Capping” describes a condition in which the tablet laminates into one or more layers.
- This invention has been directed principally to the application of specific pharmaceutical formulations incorporating isosorbide dinitrate as the active ingredient, but is applicable to other deeply grooved tablets as well.
- Isosorbide dinitrate is a potent coronary vasodilator.
- compositions containing the active ingredient would tablet in an acceptable manner because acceptable tablets could be made at this composition using conventional tools.
- a critical binder-lubricant relationship was needed to produce acceptable tablets with deep scoring tooling.
- Formula a exhibits capping, high friability, in the ranges of 7-15 Strong Cobb units (s.c.u.) hardness; the friability was 2-5% by Roche friabilator.
- Formula b repeated the behavior of Formula A on a somewhat reduced scale.
- Formula c produced satisfactory tablet hardness of 8-14 s.c.u. and friability of 0.0% at that range.
- the optimum weight is about 175 mg because at 150 mg there is a high probability of tooling contact which in turn may cause damage to the punch tips.
- Example II Following the procedure of Example I a series of formulations were prepared and deeply scored tablets were made from them. The formulations are shown in Table I.
- Table I Shown in Table I are drug amounts of 20 mg/tablet each. These correspond to a tablet containing 5 mg. of isosorbide dinitrate which is utilized in a 25 weight percent mixture with lactose being 75 weight percent. To prepare a 10 mg. isosorbide dinitrate tablet 40 mg. of drug-lactose mixture would be used (representing 10 mg. of isosorbide dinitrate). The change in dosage is balanced with the amount of lactose in the formulation while producing similar results.
- FORMULA A exhibited severe picking on the upper face of the tablet.
- FORMULA B contained the minimal level of anhydrous lactose to produce an adequate tablet. However, the tablet demonstrated poor disintegration.
- FORMULA C produced soft tablets that capped while still picking.
- FORMULA G showed adequate manufacturability as to hardness and friability.
- the tablets were free of picking.
- FORMULA I was a slugged formula which exhibited binding and picking on the tablet lower face.
- FORMULA J was a slugged formula with a higher lubricant level which produced adequate lubrication but insufficient hardness.
- the preferred weight for deeply grooved tablets is 150 to 175 mg.
- the preferred ratio of lubricant to binder is obtained when the binder constitutes 45 to 99.7 w/o and the lubricant constitutes 0.3 to 0.4 w/o of tablet exclusive of the amount of the active ingredient, fillers, extenders, flavor and the like. That is, the weight per cent of the binder and lubricant is based on the portion of the tablet composition usually referred to as q.s.
- a particularly advantageous formula weighs 175 mg. per tablet and contains 60 percent by weight microcrystalline cellulose with 0.35 percent by weight of magnesium stearate.
- the deeply scored design was also utilized in the manufacture of a chewable tablet form containing isosorbide dinitrate at a 10 mg. level.
- Formula A exhibited very high friability, capping and a narrow hardness range.
- Formula C was a wet granulated formula, and exhibited high friability, capping and inadequate chewability due to the wet binder.
- Formula D shows adequate manufacturability and chewability.
- Formula G was slugged and exhibited capping, narrow hardness range and slight picking.
- Formula H produced adequate tableting characteristics.
- the first formulation uses a directly compressed mannitol and a dextrose and corn syrup solids granulation in combination;
- the second formulation uses dextrose and corn syrup solids granulation without mannitol in direct compression.
- the preferred embodiment at which chewable deeply scored tablets can be made is for the first category with at least 20 percent by weight of microcrystalline cellulose, 31.5 percent by weight of Cellutab anhydrous, 25 percent mannitol and a range of 0.7-1.0 percent by weight of magnesium stearate or: at the second category with Cellutab anhydrous and a minimum of 0.35 percent by weight of magnesium stearate.
- Table II present the compositions of pharmaceutical tablets manufactured by three basic methods; direct compression, dry granulation, and wet granulation. These examples are not to be construed as limiting the scope of this invention which may only be determined by reference to the appended claims.
Abstract
The disclosure is directed to formulations for tablets which are to be deeply grooved to facilitate breaking into predetermined portions by the user. A critical tablet weight for deeply grooved tablets is disclosed.
Description
This invention relates to novel formulations for tablets which are to be deeply grooved. Deeply grooved tablets are those in which the groove is one-third to two-thirds of the total tablet thickness. Such tablets are shown for instance in U.S. Pat. No. 224,591 and in copending applications Ser. No. 386,142 filed Aug. 6, 1973 which is a continuation-in-part of Ser. No. 312,065 filed Dec. 4, 1972 and now abandoned which was in turn a combination of Ser. No. 114,926 filed Feb. 12, 1971 and Ser. No. 124,894 filed Mar. 16, 1971. The foregoing patent and applications were all filed by Edwin F. Roberts and assigned to the assignee of this application. The tablet design allows for easy, simple and accurate division of a pharmaceutical tablet.
In the manufacture of tablets a groove, or bisect, or score, may be formed on one of the tablet faces. The groove facilitates breaking of the tablet into two parts by applying pressure while the tablet is held between two fingers or in both hands.
In the pharmaceutical industry dividing a tablet into two or more accurate predetermined parts permits the administration of two or more doses of the active ingredient, or drug, contained in the tablet. Potent drugs are frequently incorporated in small amounts into a total tablet formulation, and the capability to divide the tablet accurately allows for a saving by not having to formulate, package and distribute different sized tablets for a portion of the dose and for the full dose. In addition, it is often beneficial to the chemical stability of the drug to incorporate the full dose in the smallest tablet size available. The inclusion of one-half of that dose in a tablet of similar size decreases the relation of drug to excipients twofold, thus in many cases also increasing the possibility of drug degradation due to drug-excipient interaction.
Some of the problems that arise in the production of regularly grooved tablets are:
1. Depending on its hardness, it is sometimes impossible to break the tablet although it is scored.
2. Scores do not always assure precise division of the tablet.
3. Pharmaceutical tablets of smaller sizes do not allow for ease of holding and breaking; in which case the patient very often resorts to using other means of dividing the tablet which results in losing parts of it or obtaining uneven parts or both.
Typical deeply scored tablets to which the present invention is applicable are shown in the drawings in which:
FIG. 1 is an isometric view of a pharmaceutical tablet employing a deeply scored design;
FIG. 2 is a top plan view thereof;
FIG. 3 is a side elevational view thereof as seen at right angles to FIG. 2;
FIG. 4 is an end elevational view thereof as seen at right angles to FIG. 2;
FIG. 5 is an end elevational view of a pharmaceutical tablet embodying a modification of the form illustrated in FIG. 4; and
FIG. 6 is a bottom view of the embodiments of FIGS. 1 and 5.
The deeply grooved tablet design presents tablet compression characteristics which are not typical of the manufacturing of conventional pharmaceutical tablets. While tablets are usually compacted between uniform surfaces, flat or concave, the deeply grooved tablet design presents a non-uniform compressing surface on one tablet face and a uniform face, spherical or flat, on the other. Such a multiplanar surface presents a process of physical compaction which does not produce the results expected from a conventional compressed tablet. In the process of compaction, the multiplanar surface applies forces, the resultant of which is not vertical. This results in non-uniform stress distribution within the tablet as an independent unit which in turn causes tablet capping and the inadequate imprinting or embossing of indicia of any of its surfaces. In addition, the uneven distribution of stresses results in varying levels of lubrication effectivenss of the tablet planes in contact with the press tooling which, in turn, causes "picking" of material off the tablet surface. To overcome this phenomenon requires a highly cohesive mixture which is at the same time sufficiently lubricated to enable friction-free tooling to tablet contact on all tablet planes. In practice the tablet formulator has to balance the lubricant level against the binder level because the increase of the former will diminish the effect of the latter until the critical region of such action is surpassed.
"Picking" and "sticking" are words of art, meaning part of the tablet sticks to the tips of the upper or lower punch. "Capping" describes a condition in which the tablet laminates into one or more layers.
This invention has been directed principally to the application of specific pharmaceutical formulations incorporating isosorbide dinitrate as the active ingredient, but is applicable to other deeply grooved tablets as well. Isosorbide dinitrate is a potent coronary vasodilator.
It was originally presumed that existing, acceptable, direct compression, tableting compositions could be adequately compressed with deep scoring tooling. Two such compositions were evaluated and surprisingly, it was found that acceptable tablets could not be made. Using a placebo composition (one without an active ingredient) similar to a presently used acceptable isosorbide dinitrate tablet composition, it was determined that, unexpectedly, a total tablet weight was critical to obtain acceptable tablets. To minimize the problems caused by stress non-uniformity, an optimal weight was found where after sufficient compression the distance between the apex of the convex side of the tablet and the bottom of the V-shaped opening on top will be minimal while still allowing for adequate manufacturability.
Having established the critical tablet weight, it was expected that compositions containing the active ingredient would tablet in an acceptable manner because acceptable tablets could be made at this composition using conventional tools. However, unexpectedly, it was found that a critical binder-lubricant relationship was needed to produce acceptable tablets with deep scoring tooling.
Four experiments were designed to select the most optimal tablet weight for the easy-break design. The data is shown in Example I. CL EXAMPLE I
All experiments were run in duplicates from one stock powder mixture and directly compressed on a rotary tablet press. The material run was an optimal placebo mixture as described below:
__________________________________________________________________________
FORMULAE A B C D
__________________________________________________________________________
Lactose hydrous U.S.P.
qs qs qs qs
Microcrystalline Cellulose
25 w/o
25 w/o
25 w/o
25 w/o
Magnesium Stearate U.S.P.
0.25 w/o
0.25 w/o
0.25 w/o
0.25 w/o
Total Table Weight
230 mg
200 mg
175 mg
150 mg
__________________________________________________________________________
The pharmaceutical term "qs" is an abbreviation of the Latin phrase quantum sufficiat which means as much as suffices. The abbreviation "w/o" means percent by weight.
The results were as follows:
Formula a: exhibits capping, high friability, in the ranges of 7-15 Strong Cobb units (s.c.u.) hardness; the friability was 2-5% by Roche friabilator.
Formula b: repeated the behavior of Formula A on a somewhat reduced scale.
Formula c: produced satisfactory tablet hardness of 8-14 s.c.u. and friability of 0.0% at that range.
Formula d: produced satisfactory tablets.
Initially it was tried to utilize a conventional isosorbide dinitrate formula and weight for the easy-break tableting tools. It was expected that the design would perform adequately at a total weight of 230 milligrams (mg). Surprisingly the tablets made at this weight were unsatisfactory, and evidenced capping, high friability in addition to insufficient tablet hardness. An attempt was made to solve the problem by selecting the most adequate tablet weight to achieve better manufacturability, but was unsuccessful.
The weight selection experiments indicated that in order to achieve adequate tableting parameters with deep scoring tooling the tablet weight will have to be under 200 mg. The optimum weight is about 175 mg because at 150 mg there is a high probability of tooling contact which in turn may cause damage to the punch tips.
Once the weight problem was solved, no further problems were anticipated. However, upon careful scrutiny of the tableting performance there was found an unexpected problem in the binder and lubricant relationship. "Picking" and "sticking" were found in some cases, and soft tablets with capping in others. In order to resolve the problem a set of experiments was designed to determine the critical nature of the binder and lubricant levels. The experiments are shown in Example II:
Following the procedure of Example I a series of formulations were prepared and deeply scored tablets were made from them. The formulations are shown in Table I.
TABLE I
__________________________________________________________________________
PERCENT OF TOTAL TABLET WEIGHT
FORMULA A B C D E F G H I J K
__________________________________________________________________________
Microcrystalline Cellulose
25 25 25 25 45 45 25 25 25 60
*Solka-floc 10
Lactose hydrous qs qs qs qs qs qs qs qs qs qs
Lactose, anhydrous 63
Dicalcium Phosphate
**Sta-Rx 1500 74
Magnesium Stearate
0.22
0.3
0.22
0.22
0.3
0.22
0.35
0.3
0.3
0.4
0.35
Stearic Acid
***Stero-Tex 0.50
Talc 2
Isosorbide Dinitrate
Trituration 20.0
20.0
20.0
20.0
20.0
20.0
20.0
20.0
20.0
20.0
20.0
mg mg mg mg mg mg mg mg mg mg mg
__________________________________________________________________________
Total Weight mg 175
175
175
175
175
175
175
175
175
175
175
__________________________________________________________________________
Formulaes A through H with the exception of G did not exhibit adequate
manufacturability in a direction compression process.
*Purified Cellulose, Brown Co.
**Directly compressible starch
***Edible vegetable oil, powdered lubricant
Shown in Table I are drug amounts of 20 mg/tablet each. These correspond to a tablet containing 5 mg. of isosorbide dinitrate which is utilized in a 25 weight percent mixture with lactose being 75 weight percent. To prepare a 10 mg. isosorbide dinitrate tablet 40 mg. of drug-lactose mixture would be used (representing 10 mg. of isosorbide dinitrate). The change in dosage is balanced with the amount of lactose in the formulation while producing similar results.
The results were as follows:
FORMULA A exhibited severe picking on the upper face of the tablet.
FORMULA B contained the minimal level of anhydrous lactose to produce an adequate tablet. However, the tablet demonstrated poor disintegration.
FORMULA C produced soft tablets that capped while still picking.
FORMULA D exhibited insufficient hardness range and picking on both tablet faces.
FORMULA E showed insufficient binding resulting in very soft tablets having high friability.
FORMULA F showed inadequate performance because of slight pick.
FORMULA G showed adequate manufacturability as to hardness and friability. The tablets were free of picking.
FORMULA H showed insufficient hardness with picking on bottom face.
FORMULA I was a slugged formula which exhibited binding and picking on the tablet lower face.
FORMULA J was a slugged formula with a higher lubricant level which produced adequate lubrication but insufficient hardness.
FORMULA K showed excellent manufacturability for all parameters.
Based on the foregoing it was determined that tablets made of conventional pharmaceutical ingredients would manufacture adequately at weights under 200 mg. utilizing a deeply scored design. In addition, a great amount of experimentation and design was spent on the tablet formulation to overcome the critical nature of its binder and lubricant dependence.
From the foregoing the preferred weight for deeply grooved tablets is 150 to 175 mg. The preferred ratio of lubricant to binder is obtained when the binder constitutes 45 to 99.7 w/o and the lubricant constitutes 0.3 to 0.4 w/o of tablet exclusive of the amount of the active ingredient, fillers, extenders, flavor and the like. That is, the weight per cent of the binder and lubricant is based on the portion of the tablet composition usually referred to as q.s.
Only microcrystalline cellulose of the binders presently available on the market has been found to be useful in deep grooved tablet compositions. Only the stearates, including stearic acid, of the lubricants presently available on the market have been found to be useful in deep grooved tablet compositions.
A particularly advantageous formula weighs 175 mg. per tablet and contains 60 percent by weight microcrystalline cellulose with 0.35 percent by weight of magnesium stearate.
For assuring of disintegration and dissolution reproducibility the use of 1 percent Amberlite is optional and has been tested to that effect.
Preparation of 10 mg. Isosorbide Dinitrate Chewable Tablets
The deeply scored design was also utilized in the manufacture of a chewable tablet form containing isosorbide dinitrate at a 10 mg. level.
Again, in this formula it was found necessary to resort to a lower tablet weight of 175 mg. In addition, because the design of a chewable tablet requires the incorporation of a chewable carrier, it was necessary to evaluate different chewable materials to obtain a sufficiently cohesive and well lubricated direct compression formula. The data obtained in those experiments is shown in Table II in which the tablets were prepared as described in Example I.
TABLE II
__________________________________________________________________________
CHEWABLE TABLETS
FORMULAE A B C D E F G H
__________________________________________________________________________
Isosorbide Dinitrate (25%)
40 mg
40 mg
40 mg
40.0 mg
40 mg
40 mg
40.0 mg
40.0 mg
Lactose mixture
*Nutab qs qs
Mannitol U.S.P. qs 20% 20% 20% qs
**Cellutab, anhydrous 31.5%
31.5%
31.5% qs
Microcrystalline Cellulose
25.0%
20% 25% 25% 25% 25% 20%
Solka floc 8.0%
Magnesium Stearate U.S.P.
0.6%
0.7%
1.0%
1.0% 0.5%
0.9%
0.9%+0.9%
0.35%
FD&C Yellow No. 5 Lake
0.1%
0.1%
0.4%
0.4% 0.4%
0.4%
0.4% 0.4%
Sodium Saccharine N.F. 0.08%
0.08%
0.08%
-- 0.08% --
Methyl Cellulose 400 cps
.07%
Lemon Oil, spray dried 1.7%
1.7% 1.7%
1.7%
1.7%
1.7%
Total Tablet Weight
222.5
196 190 175.0
175 175 175.0 175
mg mg mg mg mg mg mg mg
__________________________________________________________________________
*Sucrose, invert sugar, starch, magnesium stearate direct compression
granulation.
**Dextrose and corn syrup solids granulation.
Formulae A, B, D, E and F are directly compressed.
Formula A exhibited very high friability, capping and a narrow hardness range.
In Formula B the weight has been reduced, but tablets still exhibit heavy capping and friability with very low hardness.
Formula C was a wet granulated formula, and exhibited high friability, capping and inadequate chewability due to the wet binder.
Formula D shows adequate manufacturability and chewability.
In Formula E reduced lubricant level results in heavy picking on both tablet faces.
In Formula F eliminating the sweetener from Formula D maintains adequate manufacturability with improved taste.
Formula G was slugged and exhibited capping, narrow hardness range and slight picking.
Formula H produced adequate tableting characteristics.
From the foregoing it was concluded that 10 mg. chewable tablets were successfully made in two formulations:
1. The first formulation uses a directly compressed mannitol and a dextrose and corn syrup solids granulation in combination;
2. The second formulation uses dextrose and corn syrup solids granulation without mannitol in direct compression.
The choice between these two categories depends strictly on personal taste preference. Both formulae will produce similarly adequate results.
The preferred embodiment at which chewable deeply scored tablets can be made is for the first category with at least 20 percent by weight of microcrystalline cellulose, 31.5 percent by weight of Cellutab anhydrous, 25 percent mannitol and a range of 0.7-1.0 percent by weight of magnesium stearate or: at the second category with Cellutab anhydrous and a minimum of 0.35 percent by weight of magnesium stearate.
The incorporation of an ingredient which would serve as a chewable carrier, one which imparts a certain pallatable feeling, sweetness and desirable chewability, presents additional variables to the ones already described above. When processing and formulating for such purpose, it is necessary to consider the properties producing the resulting chewable quality of the tablet, that is hardness, taste and pallatability. The majority of chewable carriers, apart from the granulated natural sugars and their derivatives, do not lend themselves to direct compression and tend to lose some of their taste upon any granulation method.
The examples illustrated in Table II present the compositions of pharmaceutical tablets manufactured by three basic methods; direct compression, dry granulation, and wet granulation. These examples are not to be construed as limiting the scope of this invention which may only be determined by reference to the appended claims.
Claims (5)
1. A pharmaceutical tablet which is adequately imprinted with indicia or embossing and scored to form a groove which is one-third to two-thirds the depth of the total tablet thickness to facilitate separation into subdivisions containing substantially equal amounts of a pharmaceutically active ingredient comprising a directly compressed formulation of 5 to 10 milligrams of an active ingredient, the remainder being 45 to 99.7 percent by weight of microcrystalline cellulose and 0.3 to 0.4 percent by weight of magnesium stearate, along with fillers, extenders, flavoring and the like.
2. The tablet as defined in claim 1 in which the total tablet weight is 150 to 175 milligrams.
3. A tablet as defined in claim 1 in which the total tablet weight is about 175 milligrams.
4. A tablet as defined in claim 1 in which the microcrystalline cellulose is present in the amount of 60 percent by weight and the magnesium stearate is present in the amount of 0.35 percent by weight.
5. A tablet as defined in claim 1 in which the active ingredient is 5 to 10 milligrams of isosorbide dinitrate. .Iadd. 6. A pharmaceutical tablet which is adequately imprinted with indicia or embossing and scored to form a groove which is one-third to two-thirds the depth of the total thickness to facilitate separation into subdivisions containing substantially equal amounts of a pharmaceutically active ingredient comprising a directly compressed formulation of an effective amount of an active ingredient, the remainder being 45 to 99.7 percent by weight of microcrystalline cellulose and 0.3 to 0.4 percent by weight of magnesium stearate, along with fillers, extenders, flavoring and the like. .Iaddend.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/666,559 USRE29077E (en) | 1972-12-06 | 1976-03-15 | Tablet formulation |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US312469A US3883647A (en) | 1972-12-06 | 1972-12-06 | Tablet formulation |
| US05/666,559 USRE29077E (en) | 1972-12-06 | 1976-03-15 | Tablet formulation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US312469A Reissue US3883647A (en) | 1972-12-06 | 1972-12-06 | Tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| USRE29077E true USRE29077E (en) | 1976-12-14 |
Family
ID=26978390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/666,559 Expired - Lifetime USRE29077E (en) | 1972-12-06 | 1976-03-15 | Tablet formulation |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | USRE29077E (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639458A (en) | 1985-01-22 | 1987-01-27 | Merck & Co., Inc. | Tablet and formulation |
| US4675188A (en) | 1985-08-02 | 1987-06-23 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
| US4707361A (en) | 1985-08-02 | 1987-11-17 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
| US7985419B1 (en) | 2006-12-22 | 2011-07-26 | Watson Laboratories, Inc. | Divisible tablet and associated methods |
| USD669573S1 (en) * | 2010-12-15 | 2012-10-23 | Otsuka Pharmaceutical Co., Ltd. | Tablet |
| USD941457S1 (en) * | 2020-04-07 | 2022-01-18 | Nutramax Laboratories, Inc. | Dietary supplement |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1836604A (en) * | 1929-06-01 | 1931-12-15 | Simon M Meyer | Sugar unit |
| USD91644S (en) | 1933-12-22 | 1934-03-06 | Alex Blackstone | Design for a proprietary medicine bar |
| US3146168A (en) * | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
| USD201497S (en) | 1964-09-28 | 1965-06-29 | Warner Lambert Co | Tablet |
| USD202467S (en) | 1963-10-07 | 1965-10-05 | Jacques Guilmot | Pharmaceutical tablets |
| NL6614611A (en) | 1965-10-23 | 1967-04-24 | ||
| US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
| US3723614A (en) * | 1971-01-06 | 1973-03-27 | Ciba Geigy Ag | Maltese-cross scored tablet |
-
1976
- 1976-03-15 US US05/666,559 patent/USRE29077E/en not_active Expired - Lifetime
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1836604A (en) * | 1929-06-01 | 1931-12-15 | Simon M Meyer | Sugar unit |
| USD91644S (en) | 1933-12-22 | 1934-03-06 | Alex Blackstone | Design for a proprietary medicine bar |
| US3146168A (en) * | 1962-04-10 | 1964-08-25 | Fmc Corp | Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates |
| US3336200A (en) * | 1963-05-28 | 1967-08-15 | Warner Lambert Pharmaceutical | Tablet structure |
| USD202467S (en) | 1963-10-07 | 1965-10-05 | Jacques Guilmot | Pharmaceutical tablets |
| USD201497S (en) | 1964-09-28 | 1965-06-29 | Warner Lambert Co | Tablet |
| NL6614611A (en) | 1965-10-23 | 1967-04-24 | ||
| US3723614A (en) * | 1971-01-06 | 1973-03-27 | Ciba Geigy Ag | Maltese-cross scored tablet |
Non-Patent Citations (5)
| Title |
|---|
| Battista et al., Ind. Eng. Chem. 54(9): 20-29, (1962), "Microcrystalline Cellulose." * |
| Fox et al., Cosmetic Ind. 92: 161-164, 258-261, (1963), "Microcrystalline Cellulose in Tableting." * |
| Reier et al., J. Pharm. Sci. 55(5): 510-514, (1966), "Microcrystalline Cellulose in Tableting." * |
| Reier, Dissertation Abstr. 25(5): 2933 (1964), "Microcrystalline Cellulose in Tableting." * |
| Woods, Am. Perfumer Cosmet. 80(4): 51-53, 55-60, (1965), "Microcrystalline Cellulose, A New Ingredient for Pharmaceuticals and Cosmetics." * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4639458A (en) | 1985-01-22 | 1987-01-27 | Merck & Co., Inc. | Tablet and formulation |
| US4675188A (en) | 1985-08-02 | 1987-06-23 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
| US4707361A (en) | 1985-08-02 | 1987-11-17 | Stauffer Chemical Company | Granular anhydrous dicalcium phosphate compositions suitable for direct compression tableting |
| US7985419B1 (en) | 2006-12-22 | 2011-07-26 | Watson Laboratories, Inc. | Divisible tablet and associated methods |
| USD669573S1 (en) * | 2010-12-15 | 2012-10-23 | Otsuka Pharmaceutical Co., Ltd. | Tablet |
| USD941457S1 (en) * | 2020-04-07 | 2022-01-18 | Nutramax Laboratories, Inc. | Dietary supplement |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3883647A (en) | Tablet formulation | |
| US3927194A (en) | Tablet formulation | |
| US3336200A (en) | Tablet structure | |
| US6270790B1 (en) | Soft, convex shaped chewable tablets having reduced friability | |
| EP0914818B1 (en) | Intraorally rapidly disintegrable tablet | |
| US8945618B2 (en) | Intrabuccally rapidly disintegrating tablet and a production method of the tablets | |
| US6277409B1 (en) | Protective coating for tablet | |
| CA2360102C (en) | Tablets disintegrating rapidly in the oral cavity | |
| US5501861A (en) | Fast dissolving tablet and its production | |
| US20030068373A1 (en) | Immediate release tablet | |
| US4894236A (en) | Direct compression tablet binders for acetaminophen | |
| USRE29077E (en) | Tablet formulation | |
| NZ510563A (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same | |
| WO1981002521A1 (en) | Pharmaceutical vehicle composition and process of producing same | |
| US6663889B1 (en) | Ambroxol-containing lozenge | |
| USRE29076E (en) | Tablet formulation | |
| US3594467A (en) | Long-lasting troche | |
| CA2341005C (en) | Exactly divisible tablet | |
| US3395211A (en) | Tableting process | |
| JPS61289027A (en) | Tablet | |
| NO128051B (en) | ||
| US20050271718A1 (en) | Sustained release propafenone hydrochloride capsules | |
| US20210059948A1 (en) | Cyclic orally disintegrating tablet | |
| EP0975337B1 (en) | Fast release compressed tablet of flurbiprofen | |
| JP7098008B2 (en) | Laminated tablets and their manufacturing methods |